Compare Intuitive Surgical, Inc. (ISRG) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Moderna, Inc. — how do they compare? Intuitive Surgical, Inc. trades at $423.96 (market cap $146.76B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Intuitive Surgical, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Moderna, Inc. for 59 Days on average.
| ISRG | MRNA | |
|---|---|---|
Market Cap | $146.76B | $78.65B |
Volume | 2,529,814 | 37,373,437 |
Sector | Health | Health |
52-Week High | $592.85 | $203.46 |
52-Week Low | $332.02 | $22.36 |
Typical Hold Time | 84 Days | 59 Days |
Enterprise Value | $141.54B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $423.96, up 2.28% with strong bullish momentum. The stock shows robust fundamentals with 2025 revenue reaching $10.06B and net income of $2.86B, maintaining 28.45% net margins. Recent quarters consistently beat EPS estimates, while technical indicators signal bullish moving averages. Analyst consensus remains strongly positive with 70% buy ratings and $480.78 price target, representing 13% upside potential.
ISRG's leadership in robotic surgery and expanding international presence in India and Japan provide growth catalysts, though China weakness and competitive pressures present risks. The stock's premium valuation (P/E 47.64) reflects high growth expectations, requiring continued execution. Current levels near resistance at $427 may test near-term momentum ahead of Q3 earnings.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
